An open longitudinal observational study, non-randomized, which will include the adult population, attended by the SES, in which preference will be given to those patients under treatment with drugs that can produce relevant adverse effects. It is a naturalistic study in which no pharmacological or other type of intervention will be carried out, only the information recommended in the drug data sheet (pharmacogenetic biomarkers, relevant interactions and clinical contraindications) will be provided.
Study Type
OBSERVATIONAL
Enrollment
6,445
Complejo Hospitalario Universitario de Badajoz
Badajoz, Spain
RECRUITINGEvaluation of the implementation of the Pharmacogenetics and Personalized Medicine Program "MedeA" in the Extremadura Health Service.
To analyze the implementation in the clinical routine of a pharmacogenetics and personalized medicine program in SES patients, evaluating the overall impact on the health system, and at the individual level, general modifications in the clinical response and its temporal evolution.
Time frame: December 2024
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.